Last reviewed · How we verify
NCT07354191
Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia
NA trial testing direct antiglobulin test (DAT) in Multiple Myeloma in 66 participants. Completed in 6 November 2025.
5 November 2025
Quick facts
| Lead sponsor | New Valley University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 66 |
| Start date | 15 January 2023 |
| Primary completion | 5 November 2025 |
| Estimated completion | 6 November 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- direct antiglobulin test (DAT)
- Indirect antiglobulin test (IAT)
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
New Valley University
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement. Other pathogenic mechanisms include hyper-activation of cellular immune effectors, cytokine dysregulation, and ineffective marrow compensation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07354191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other New Valley University trials
Trials by the same sponsor.
- NCT06067399 — Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemi · recruiting
- NCT06387667 — Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections · NA · not yet recruiting
- NCT07142239 — Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome · not yet recruiting
- NCT07171541 — Correlation Between OCT and Mf-ERG Findings With BCVA in Patients With Macular Dystrophy · not yet recruiting
- NCT06490731 — Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07354191 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New Valley University
- Last refreshed: 21 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07354191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing